Related Experiment Video
Updated: May 17, 2026
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Potential of human γδ T cells for immunotherapy of osteosarcoma
1Department of Orthopaedics, No. 2, Affiliated Hospital of Guilin Medical University, Guilin Medical University, No. 15, Lequn Road, Guilin 541004, People's Republic of China. lizhaoxuglm@gmail.com
Abstract:
Recurrent or metastatic osteosarcomas remain a challenging malignancy to treat. Therefore, development and testing of novel therapeutic strategies to target these patients are needed. Adoptive cellular therapy strategies are being evaluated intensively as a novel therapeutic strategy for cancer. Unlike αβ T cells requiring antigen processing and MHC-restricted peptide displayed by antigen-presenting cells, γδ T cells exhibit the potent MHC-unrestricted lytic activity against various tumors in vitro and in vivo. The recent considerable success of γδ T cell-based immunotherapy in lung metastasis of renal cell carcinoma warrants further efforts to apply this treatment to other cancers including osteosarcoma, especially recurrent and metastatic osteosarcomas. In this review, we summarize the available evidence on γδ T cell-based immunotherapy for osteosarcoma that has been achieved to date. More importantly, we discuss potential strategies of the combination of expanded γδ T cells and bisphosphonates, and modification and expansion of αβ TCR modified γδ T cells for improving its efficacy for the treatment of osteosarcoma.
Insights
Novel immunotherapy using gamma-delta (γδ) T cells shows promise for treating recurrent or metastatic osteosarcoma. Combining these cells with bisphosphonates or modifying them may enhance treatment efficacy.
Area of Science:
- Immunology
- Oncology
- Cellular Therapy
Background:
- Recurrent or metastatic osteosarcomas are difficult to treat, necessitating novel therapeutic approaches.
- Adoptive cellular therapy is a promising cancer treatment strategy.
- Gamma-delta (γδ) T cells offer potent, MHC-unrestricted tumor cell lysis, unlike alpha-beta (αβ) T cells.
Purpose of the Study:
- To review current evidence on γδ T cell-based immunotherapy for osteosarcoma.
- To explore strategies for enhancing γδ T cell therapy efficacy in osteosarcoma treatment.
Main Methods:
- Review of existing literature on γδ T cell immunotherapy for osteosarcoma.
- Discussion of combination strategies involving expanded γδ T cells and bisphosphonates.
- Exploration of modified αβ T cell receptor (TCR) engineered γδ T cells.
Main Results:
- γδ T cells demonstrate potent anti-tumor activity against various cancers.
- Successful application of γδ T cell immunotherapy in other cancers suggests potential for osteosarcoma.
- Potential combination therapies and cell modifications could improve treatment outcomes.
Conclusions:
- γδ T cell immunotherapy is a viable strategy for osteosarcoma, particularly for recurrent or metastatic cases.
- Combining expanded γδ T cells with bisphosphonates may enhance efficacy.
- Engineering γδ T cells with αβ TCR modifications offers a pathway to improved osteosarcoma treatment.
